Paul E Stach

Title: Paul E Stach: Innovator in Pharmaceutical Formulations

Introduction

Paul E Stach is a notable inventor based in Plymouth, MN (US), recognized for his contributions to pharmaceutical formulations. He holds 3 patents that focus on innovative drug delivery systems, particularly in the realm of sustained release oral dosage forms.

Latest Patents

Stach's latest patents include the development of GABA analog prodrug sustained release oral dosage forms. These formulations, specifically the gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are designed to treat or prevent various diseases and disorders for which gabapentin is therapeutically effective. The sustained release mechanism enhances the efficacy and patient compliance of the medication.

Career Highlights

Throughout his career, Stach has made significant strides in the pharmaceutical industry. He is currently associated with Xenoport, Inc., where he continues to innovate in drug formulation and delivery systems. His work has contributed to advancements in therapeutic options available to patients.

Collaborations

Stach has collaborated with esteemed colleagues such as Kenneth C Cundy and Srikonda Sastry, further enhancing the impact of his work in the field of pharmaceuticals.

Conclusion

Paul E Stach's innovative work in sustained release oral dosage forms exemplifies the importance of advancements in pharmaceutical technology. His contributions continue to influence the treatment landscape for various medical conditions.